Intraoperative transfection of vein grafts with the NFkappaB decoy in a canine aortocoronary bypass model: a strategy to attenuate intimal hyperplasia. 2002

Takuji Shintani, and Yoshiki Sawa, and Toshiki Takahashi, and Goro Matsumiya, and Nariaki Matsuura, and Yuji Miyamoto, and Hikaru Matsuda
Department of Surgery, Osaka University Graduate School of Medicine, Suita, Japan.

BACKGROUND The nuclear transcriptional factor NFkappaB is reported to play an important role in the expression of genes for neutrophil and macrophage chemotactic factors, adhesion molecules, and cell cycle-regulating proteins. In aortocoronary bypass surgery, the saphenous vein often develops vein graft disease. Here, we investigated whether transfection of a cis element decoy oligodeoxynucleotide of NFkappaB (NFkappaB decoy) into the vein graft wall suppresses neointimal hyperplasia and the differentiation of medial smooth muscle cells. METHODS We established a canine aortocoronary bypass grafting model that has a saphenous vein graft between the left anterior descending coronary artery and the descending aorta. Pressure-mediated transfection of a scrambled (SD group; n = 5) or NFkappaB decoy (ND group; n = 5) into the graft wall was performed intraoperatively. The grafts were gently harvested at 4 weeks postoperative, and the middle portion of the graft was examined histopathologically. RESULTS The average neointimal area of the ND group was significantly suppressed (SD group, 2.63 +/- 1.00 mm2 vs ND group, 0.88 +/- 0.66, p < 0.05), and the differentiation and proliferation of the medial smooth muscle cells in the ND group were also suppressed (proliferating cell nuclear antigen index: SD group, 56 +/- 24 vs ND, 13 +/- 4, p < 0.05). CONCLUSIONS These results demonstrated the efficacy of intraoperative transfection of the NFkappaB decoy into the vein graft wall for attenuation of neointima formation.

UI MeSH Term Description Entries
D006965 Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells. Hyperplasias
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D009838 Oligodeoxyribonucleotides A group of deoxyribonucleotides (up to 12) in which the phosphate residues of each deoxyribonucleotide act as bridges in forming diester linkages between the deoxyribose moieties. Oligodeoxynucleotide,Oligodeoxyribonucleotide,Oligodeoxynucleotides
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001026 Coronary Artery Bypass Surgical therapy of ischemic coronary artery disease achieved by grafting a section of saphenous vein, internal mammary artery, or other substitute between the aorta and the obstructed coronary artery distal to the obstructive lesion. Aortocoronary Bypass,Bypass, Coronary Artery,Bypass Surgery, Coronary Artery,Coronary Artery Bypass Grafting,Coronary Artery Bypass Surgery,Aortocoronary Bypasses,Artery Bypass, Coronary,Artery Bypasses, Coronary,Bypass, Aortocoronary,Bypasses, Aortocoronary,Bypasses, Coronary Artery,Coronary Artery Bypasses
D012501 Saphenous Vein The vein which drains the foot and leg. Saphenous Veins,Vein, Saphenous,Veins, Saphenous
D014162 Transfection The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES. Transfections
D016328 NF-kappa B Ubiquitous, inducible, nuclear transcriptional activator that binds to enhancer elements in many different cell types and is activated by pathogenic stimuli. The NF-kappa B complex is a heterodimer composed of two DNA-binding subunits: NF-kappa B1 and relA. Immunoglobulin Enhancer-Binding Protein,NF-kappa B Complex,Nuclear Factor kappa B,Transcription Factor NF-kB,kappa B Enhancer Binding Protein,Ig-EBP-1,NF-kB,NF-kappaB,Nuclear Factor-Kappab,Complex, NF-kappa B,Enhancer-Binding Protein, Immunoglobulin,Factor NF-kB, Transcription,Factor-Kappab, Nuclear,Ig EBP 1,Immunoglobulin Enhancer Binding Protein,NF kB,NF kappa B Complex,NF kappaB,NF-kB, Transcription Factor,Nuclear Factor Kappab,Transcription Factor NF kB

Related Publications

Takuji Shintani, and Yoshiki Sawa, and Toshiki Takahashi, and Goro Matsumiya, and Nariaki Matsuura, and Yuji Miyamoto, and Hikaru Matsuda
September 1985, Cardiovascular research,
Takuji Shintani, and Yoshiki Sawa, and Toshiki Takahashi, and Goro Matsumiya, and Nariaki Matsuura, and Yuji Miyamoto, and Hikaru Matsuda
January 2004, The Journal of thoracic and cardiovascular surgery,
Takuji Shintani, and Yoshiki Sawa, and Toshiki Takahashi, and Goro Matsumiya, and Nariaki Matsuura, and Yuji Miyamoto, and Hikaru Matsuda
December 2005, The Journal of thoracic and cardiovascular surgery,
Takuji Shintani, and Yoshiki Sawa, and Toshiki Takahashi, and Goro Matsumiya, and Nariaki Matsuura, and Yuji Miyamoto, and Hikaru Matsuda
October 2010, Journal of cardiovascular pharmacology,
Takuji Shintani, and Yoshiki Sawa, and Toshiki Takahashi, and Goro Matsumiya, and Nariaki Matsuura, and Yuji Miyamoto, and Hikaru Matsuda
September 2008, Cardiovascular research,
Takuji Shintani, and Yoshiki Sawa, and Toshiki Takahashi, and Goro Matsumiya, and Nariaki Matsuura, and Yuji Miyamoto, and Hikaru Matsuda
April 2008, Journal of cardiothoracic surgery,
Takuji Shintani, and Yoshiki Sawa, and Toshiki Takahashi, and Goro Matsumiya, and Nariaki Matsuura, and Yuji Miyamoto, and Hikaru Matsuda
May 1993, Journal of vascular surgery,
Takuji Shintani, and Yoshiki Sawa, and Toshiki Takahashi, and Goro Matsumiya, and Nariaki Matsuura, and Yuji Miyamoto, and Hikaru Matsuda
July 2005, Annals of vascular surgery,
Takuji Shintani, and Yoshiki Sawa, and Toshiki Takahashi, and Goro Matsumiya, and Nariaki Matsuura, and Yuji Miyamoto, and Hikaru Matsuda
June 2005, The Journal of thoracic and cardiovascular surgery,
Takuji Shintani, and Yoshiki Sawa, and Toshiki Takahashi, and Goro Matsumiya, and Nariaki Matsuura, and Yuji Miyamoto, and Hikaru Matsuda
August 1983, Cardiovascular research,
Copied contents to your clipboard!